PARP Inhibitors in Cancer Diagnosis and Therapy.

Volume: 27, Issue: 6, Pages: 1585 - 1594
Published: Mar 15, 2021
Abstract
Targeting of PARP enzymes has emerged as an effective therapeutic strategy to selectively target cancer cells with deficiencies in homologous recombination signaling. Currently used to treat BRCA-mutated cancers, PARP inhibitors (PARPi) have demonstrated improved outcome in various cancer types as single agents. Ongoing efforts have seen the exploitation of PARPi combination therapies, boosting patient responses as a result of drug synergisms....
Paper Details
Title
PARP Inhibitors in Cancer Diagnosis and Therapy.
Published Date
Mar 15, 2021
Volume
27
Issue
6
Pages
1585 - 1594
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.